Article Text

Download PDFPDF
Remaining controversies in the upfront management of advanced ovarian cancer
  1. M. S. Mano,
  2. A. Awada,
  3. A. Minisini,
  4. G. Atalay,
  5. L. D. Lago,
  6. F. Cardoso and
  7. M. Piccart
  1. Unité de Chimiothérapie, Institut Jules Bordet, Brussels, Belgium
  1. Address correspondence and reprint requests to: Max Mano, Beatson Oncology Centre, Western Infirmary, Dumbarton Rd., Glasgow G11 6NT, UK. Email: max.mano{at}


Ovarian cancer (OC) is one of the leading causes of cancer-related death in women. In the last decades, a lot of energy and resources have been put into a number of clinical trials, with some success. Nevertheless, the prognosis of patients diagnosed with advanced disease remains extremely poor. As research moved forward, some crucial questions with regard to the optimal upfront management of patients with advanced OC (AOC) have remained unanswered. In this article, we review the rationale behind these controversial issues, and provide the levels of evidence supporting the current recommendations for AOC management.

  • ovarian cancer
  • chemotherapy
  • debulking surgery

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.